Application Methods: IHC-Leica® Bond™, Immunofluorescence (Immunocytochemistry), Immunohistochemistry (Paraffin)
Background: Mucins are a family of macromolecules that line and protect the respiratory epithelium from microbes and pollutants in the local environment. Of the family members that are known to date, some are produced in a cell type and tissue-specific manner, suggesting distinct biological roles for members. Some members polymerize after secretion to form gel-like substances that coat the epithelial layer. MUC5AC and MUC5B are members of the family that polymerize in this manner. Others do not polymerize, and others yet, have a transmembrane domain and remain physically attached to the epithelia (1). While it is known that mucins are protective to the respiratory epithelium, it has been reported that changes in expression of mucins are associated with several forms of lung disease such as cystic fibrosis, COPD, asthma, pulmonary fibrosis, and others (2,3,4,1). Multiple epithelial malignancies have been described to show changes in expression, localization, and glycosylation of MUC5AC. This wide association with multiple malignancy types has led to the emergence of MUC5AC as both a prognostic and therapeutic target for cancer (5).
Application Methods: Flow Cytometry, IHC-Leica® Bond™, Immunofluorescence (Immunocytochemistry), Immunohistochemistry (Paraffin), Western Blotting
Background: Human p14 ARF (p19 ARF in mouse) is a pro-apoptotic cell cycle regulator frequently inactive in human tumors (1). Basal expression of p14 ARF is low in most cell types, but accumulation of this protein occurs in response to oncogene expression (2,3). Increased p14 ARF levels facilitate MDM2 degradation, leading to increased p53 protein levels and subsequent cell cycle arrest and/or apoptosis (4). While most p14 ARF signaling has traditionally thought to be p53-dependent, more recent reports have described p53-independent p14 ARF signaling leading to cell cycle arrest and apoptosis (5,6).